- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02716233
A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents (CAALL-F01)
A still major question in the field of acute lymphoblastic leukemia (ALL) in children - an extremely heterogeneous disease though curable in 80-90% of children and 70-80% of the adolescents - is the optimal use of L-asparaginase (ASNase). It is known that administering ASNase results in the depletion of asparagine circulating in the blood, which starves the leukemic cells and results in their death. But indeed the use of ASNase varies between protocols considering the different brands, the dose and the administration modalities. Oncaspar (PEGylated E. coli asparaginase, pegaspargase) was thus developed with the goal of reducing the immunogenicity of the native ASNase.
This is a French prospective multicentric cohort study of children and adolescents with ALL, stratified on (i) the type of ALL ( B vs T) and (ii) the anticipated risk (stratified in 3 groups for childhood B-cell precursor (BCP)-ALL and 2 groups for T-cell ALL).
It aims to answer to two different issues:
- Randomized question: what is the best way to administer pegaspargase? A cohort of children and adolescents with standard or medium risk ALL will be randomized to receive during induction either one infusion of ONCASPAR® 2500 IU/m2 at D12 or two infusions of ONCASPAR® at 1250 IU/m2 each at D12 and D26. Patients will then receive 2500 IU/m2 or 1250 IU/m2 per dose during consolidation and delayed intensification according to the initial arm of randomization.
- Non randomized question: In the High/Very High Risk groups, a non randomized intensification of the scheme of asparaginase administration is proposed during induction therapy: 2 infusions of 2500 IU/m2/day (D12 and D26) will be administered. All patients will receive 2500 IU/m2 per dose during consolidation and delayed intensifications.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: André Baruchel, MD
- Phone Number: +33 1 40 03 53 88
- Email: andre.baruchel@aphp.fr
Study Contact Backup
- Name: Yves Bertrand, MD
- Phone Number: +33 4 69 16 65 70
- Email: yves.bertrand@ihope.fr
Study Locations
-
-
-
Amiens, France, 80054
- Recruiting
- CHU
-
Contact:
- Catherine Devoldere, MD
-
Angers, France, 49033
- Recruiting
- CHU
-
Besançon, France, 25030
- Recruiting
- CHRU
-
Contact:
- Pauline Simon, MD
-
Bordeaux, France, 33076
- Recruiting
- CHU
-
Contact:
- Yves Perel, MD
-
Brest, France, 29609
- Recruiting
- CHU
-
Contact:
- Liana Carausu, MD
-
Caen, France, 14033
- Recruiting
- CHU
-
Contact:
- Odile Minckes, MD
-
Clermont-Ferrand, France, 63003
- Recruiting
- CHU
-
Contact:
- Justyna Kanold, MD
-
Dijon, France, 21079
- Recruiting
- CHU
-
Contact:
- Elodie Colomb, MD
-
Grenoble, France, 38043
- Recruiting
- CHU
-
Lille, France, 59037
- Recruiting
- CHU
-
Contact:
- Françoise Mazingue, MD
-
Limoges, France, 87042
- Recruiting
- CHU
-
Lyon, France, 69373
- Recruiting
- Chu-Ihope
-
Contact:
- Yves Bertrand, MD
- Email: yves.bertrand@ihope.fr
-
Marseille, France, 13385
- Recruiting
- CHU
-
Contact:
- Gérard Michel, MD
-
Montpellier, France, 34295
- Recruiting
- CHU
-
Contact:
- Nicolas Sirvent, MD
-
Nancy, France, 54511
- Recruiting
- CHU
-
Contact:
- Claudine Schmitt, MD
-
Nantes, France, 44093
- Recruiting
- CHU
-
Contact:
- Caroline Thomas, MD
-
Nice, France, 06200
- Recruiting
- CHU
-
Contact:
- Pierre-Simon Rohrlich, MD
-
Paris, France, 75019
- Recruiting
- CHU Robert Debré
-
Contact:
- André Baruchel, MD
- Email: andre.baruchel@aphp.fr
-
Paris, France, 75010
- Recruiting
- CHU Saint Louis
-
Contact:
- Nicolas Boissel, MD
-
Paris, France, 75012
- Recruiting
- CHU Armand Trousseau
-
Contact:
- Arnaud Petit, MD
-
Poitiers, France, 86000
- Recruiting
- CHU
-
Contact:
- Frédéric Millot, MD
-
Reims, France, 51100
- Recruiting
- CHU
-
Contact:
- Stéphanie Gordes-Grosjean, MD
-
Rennes, France, 35203
- Recruiting
- CHU
-
Contact:
- Virginie Gandemer, MD
-
Rouen, France, 76031
- Recruiting
- CHU
-
Contact:
- Pascale Schneider, MD
-
Saint Etienne, France, 42270
- Recruiting
- CHU
-
Contact:
- Sandrine Thouvenin-Doulet, MD
-
Strasbourg, France, 67098
- Recruiting
- CHU
-
Contact:
- Patrick Lutz, MD
-
Toulouse, France, 31059
- Recruiting
- CHU
-
Contact:
- Geneviève Plat, MD
-
Tours, France, 37044
- Recruiting
- CHU
-
Contact:
- Pascale Blouin, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ALL L1 or L2
- B-lineage or T- lineage ALL
Exclusion Criteria:
- L3 (Burkitt's leukemia)
- Mixed Phenotype Acute Leukemia (WHO criteria).
- Infant ALL (age ≤ 365 days)
- Philadelphia (Ph)+/Breakpoint Cluster region (BCR)-Abelson (ABL) ALL
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 1
pegaspargase 2500 IU/m2 x 1: infusion of a conventional dose of pegaspargase during induction therapy: 2500 IU/m2x1
|
only for ALL of standard risk and medium risk
Other Names:
|
Experimental: Arm 2
pegaspargase 1250 IU/m2 x 2: fractionation of the 2500 IU/m2 pegaspargase dose in two infusions of 1250 IU/m2 each
|
only for ALL of standard risk and medium risk
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adequate (> 100 IU/L) asparaginase activity measured in the plasma at day 33 of induction therapy
Time Frame: Day 33
|
asparaginase activity > 100 IU/L
|
Day 33
|
Incidence of directly asparaginase-related severe toxicities (Grade ≥ 3 as assessed by CTCAE v4.0) observed during induction therapy
Time Frame: Between Day 12 of induction and Day 8 of consolidation
|
Incidence of severe toxicities (Grade ≥ 3) directly asparaginase-related (CNS thrombosis, pancreatitis, anaphylaxis, and hyperbilirubinemia) between Day 12 and Day 49 of treatment and anyway before Day 8 of consolidation
|
Between Day 12 of induction and Day 8 of consolidation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of asparagine depletion measured in plasma by a concentration below the Limit of Quantification (LOQ) of 0.4 micromol/L
Time Frame: Day 33 of induction
|
Day 33 of induction
|
|
Incidence of adequate (> 100 IU/L) asparaginase activity measured in the plasma at day 40 of induction therapy
Time Frame: Day 40 of induction
|
Day 40 of induction
|
|
Incidence of asparagine depletion measured in plasma by a concentration below the Limit of Quantification (LOQ) of 0.4 micromol/L
Time Frame: Day 40 of induction
|
Day 40 of induction
|
|
Incidence of antibodies against asparaginase, measured in serum
Time Frame: Day 4 of delayed intensification
|
Day 4 of delayed intensification
|
|
Incidence of silent inactivation
Time Frame: First 6-9 months
|
Silent inactivation or subclinical hypersensitivity is defined as a plasma PEGasparaginase activity level <100 IU/L at day 7+/- 1 or <20 IU/L at day 14 +/- 11 after administration in a patient without clinical symptoms of allergy
|
First 6-9 months
|
Percentage of patients without switch to Erwinia asparaginase
Time Frame: First 6-9 months
|
First 6-9 months
|
|
Percentage of patients receiving more than 95% of the intended dose of asparaginase
Time Frame: First 6-9 months
|
First 6-9 months
|
|
Morphological Complete Remission (CR) rates
Time Frame: Day 35-Day 42
|
Assessed on the whole population or on subgroups (B-Lineage ALL, T-cell ALL).
|
Day 35-Day 42
|
Minimal Residual Disease (MRD)
Time Frame: Day 35-Day 42, Day 65-Day 105
|
MRD will be assessed by Ig/T cell receptor (TCR)-based real-time quantitative (RQ)-polymerase chain reaction (PCR), assessed on the whole population or on subgroups (B-Lineage ALL, T-cell ALL). Assessed on the whole population or on subgroups (B-Lineage ALL, T-cell ALL). |
Day 35-Day 42, Day 65-Day 105
|
Cumulative Incidence of relapses
Time Frame: 5 years
|
Assessed on the whole population or on subgroups (B-Lineage ALL, T-cell ALL).
|
5 years
|
Cumulative Incidence of relapse according to site of relapse
Time Frame: 5 years
|
Bone-Marrow (BM) relapses, central nervous system (CNS) relapses, gonadal relapses, combined relapses. Assessed on the whole population or on subgroups (B-Lineage ALL, T-cell ALL). |
5 years
|
All other adverse events related to asparaginase
Time Frame: within the first 7 weeks (Day 49) of treatment and anyway before Day 8 of consolidation
|
Drug-induced hyperglycemia or diabetes, coagulopathy, allergy Non CNS thrombosis Grade 1-2 Adverse Events (AE): pancreatitis, hyperbilirubinemia
|
within the first 7 weeks (Day 49) of treatment and anyway before Day 8 of consolidation
|
Late adverse events related to asparaginase
Time Frame: after Day 49 of induction or anyway at Day 8 of consolidation or after
|
after Day 49 of induction or anyway at Day 8 of consolidation or after
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AOM10205
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Lymphoblastic Leukemia
-
National Cancer Institute (NCI)CompletedB-cell Adult Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingAcute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Adult T Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Adult L1 Acute Lymphoblastic Leukemia | Adult L2 Acute Lymphoblastic...United States
-
Autolus LimitedCompletedCD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Refractory Childhood Acute Lymphoblastic LeukemiaUnited Kingdom
-
Children's Oncology GroupNational Cancer Institute (NCI); ImmunoGen, Inc.WithdrawnRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent...
-
University of BirminghamAstraZeneca; Cancer Research UKTerminatedAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia RecurrentUnited Kingdom, Denmark, Netherlands
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Non-T, Non-B Childhood Acute Lymphoblastic LeukemiaUnited States
-
University College, LondonNot yet recruitingAcute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Graft Versus Host Disease | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved RemissionUnited States
-
Therapeutic Advances in Childhood Leukemia ConsortiumEnzon Pharmaceuticals, Inc.TerminatedLymphoblastic Leukemia, Acute, Childhood | Leukemia, Lymphoblastic, Acute | Lymphoblastic Leukemia, Acute | Leukemia, Lymphoblastic, Acute, T CellUnited States, Australia
Clinical Trials on pegaspargase 2500 IU/m2 x 1
-
Memorial Sloan Kettering Cancer CenterBristol-Myers SquibbCompletedLeukemia | Acute Lymphoblastic LeukemiaUnited States
-
Vejle HospitalTerminated
-
University of PittsburghGenentech, Inc.Completed
-
Baylor College of MedicineM.D. Anderson Cancer Center; The Methodist Hospital Research Institute; Center...CompletedNasopharyngeal CarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterTufts Medical Center; Lahey ClinicCompleted
-
National Cancer Institute (NCI)Canadian Cancer Trials GroupActive, not recruitingAcute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeUnited States, Canada, Israel, Puerto Rico
-
National Cancer Institute (NCI)Not yet recruitingT Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma
-
National Cancer Institute (NCI)Not yet recruiting
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedAcute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic LeukemiaUnited States, Canada, Australia
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedAcute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic LeukemiaUnited States